Elsevier

Ophthalmology

Volume 113, Issue 1, January 2006, Pages 48-57
Ophthalmology

Original Article
Idiopathic Juxtafoveal Retinal Telangiectasis: New Findings by Ultrahigh-Resolution Optical Coherence Tomography

https://doi.org/10.1016/j.ophtha.2005.08.016Get rights and content

Objective

To investigate the capabilities of ultrahigh-resolution optical coherence tomography (UHR OCT); to compare with the commercially available OCT standard-resolution system, StratusOCT, for imaging of idiopathic juxtafoveal retinal telangiectasis (IJT); and to demonstrate that UHR OCT provides additional information on disease morphology, pathogenesis, and management.

Design

Retrospective, observational, interventional case series.

Participants

Nineteen eyes of 10 patients diagnosed with IJT in at least one eye.

Method

All patients were imaged with UHR OCT and StratusOCT at the same visit. A subset of patients was also imaged before and after treatment of IJT.

Main Outcome Measures

Ultrahigh- and standard-resolution cross-sectional tomograms of IJT pathology.

Results

Using both standard- and ultrahigh-resolution OCT, we identified the following features of IJT: (1) a lack of correlation between retinal thickening on OCT and leakage on fluorescein angiography, (2) loss and disruption of the photoreceptor layer, (3) cystlike structures in the foveola and within internal retinal layers such as the inner nuclear or ganglion cell layers, (4) a unique internal limiting membrane draping across the foveola related to an underlying loss of tissue, (5) intraretinal neovascularization near the fovea, and (6) central intraretinal deposits and plaques. In 63% of cases, the presence of abnormal vessels and a discontinuity of the photoreceptor layer correlated with visual acuity.

Conclusions

Ultrahigh-resolution OCT improves visualization of the retinal pathology associated with IJT and allows identification of new features associated with it. Some of these features, such as discontinuity of the photoreceptor layer, are revealed only by UHR OCT.

Section snippets

Materials and Methods

A prototype clinical UHR OCT system suitable for performing studies in an ophthalmology clinic was developed. A femtosecond titanium:sapphire laser with a ∼125-nm bandwidth centered at the wavelength of 815 nm was developed and used as the OCT imaging light source.22 The UHR OCT system achieved axial imaging resolutions of ∼3 μm in the eye. The UHR OCT prototype system was integrated on a slit-lamp biomicroscope that was adapted with a charge-coupled device to provide a video image of the

Results

Standard-resolution and UHR OCT images of a normal macula are presented in Figure 1. The intraretinal layer morphology in the OCT images correlates well with the histological morphology of the retina in the macular region.24 The nerve fiber layer and the plexiform layers are more optically backscattering than the nuclear layers and presented as red, yellow, or bright green false color in the OCT images.25, 26, 27, 28 In both OCT images, the first highly backreflecting layer is the nerve fiber

Discussion

A comparative imaging study was performed using the UHR OCT and StratusOCT systems on patients with clinically diagnosed IJT. Both OCT systems can noninvasively acquire retinal images that are capable of differentiating most major intraretinal layers, such as the retinal nerve fiber, inner plexiform, inner nuclear, outer plexiform, and outer nuclear, as previously demonstrated on other pathologies.9, 10, 20, 21, 25, 26 In our study, the StratusOCT, at its best resolution, is capable of

References (30)

  • J.D. Gass et al.

    Idiopathic juxtafoveolar retinal telangiectasis

    Arch Ophthalmol

    (1982)
  • U. Menchini et al.

    Bilateral juxtafoveolar telangiectasis in monozygotic twins

    Am J Ophthalmol

    (1999)
  • M.J. Potter et al.

    Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis

    Am J Ophthalmol

    (2001)
  • M. Cahill et al.

    Classification of the spectrum of Coats’ disease as subtypes of idiopathic retinal telangiectasis with exudation

    Acta Ophthalmol Scand

    (2001)
  • G. Trabucchi et al.

    Idiopathic juxtafoveolar retinal telangiectasis and pigment epithelial hyperplasiaan optical coherence tomographic study

    Arch Ophthalmol

    (1999)
  • Cited by (116)

    • Non-vasogenic cystoid maculopathies

      2022, Progress in Retinal and Eye Research
      Citation Excerpt :

      Structural OCT shows the presence of macular cystoid spaces in different retinal layers. Inner macular cystoid spaces are located immediately behind the ILM while outer cavitations disrupt the ONL and the EZ (Gaudric et al., 2006; Paunescu et al., 2006; Yannuzzi et al., 2006). FA shows a mild leakage and staining of the retinal tissue around the telangiectasia, but interestingly, the larger cystoid spaces visible on OCT in the foveal center do not fill with dye (Koizumi et al., 2006) (Fig. 24).

    • When is macular edema not macular edema? An update on macular telangiectasia type 2

      2015, Taiwan Journal of Ophthalmology
      Citation Excerpt :

      Furthermore intraretinal hyporeflective spaces, that have been named as internal limiting membrane drape, cyst, cystoid, or pseudocystoid spaces by different authors, are commonly seen but are usually not related to retinal thickening or fluorescein angiographic leakage21,34–41 (Fig. 6). Interestingly, foveal thickness is decreased in most patients with Mac Tel 2.11,33–37,42 Spectral domain OCT has also documented the presence of outer retina abnormalities1 (Fig. 5).

    View all citing articles on Scopus

    Manuscript no. 2005-357.

    Supported in part by the National Institutes of Health, Bethesda, Maryland (contract nos.: RO1-EY11289-16, R01-EY13178, P30-EY13078); National Science Foundation, Arlington, Virginia (contract no.: ECS-0119452); Air Force Office of Scientific Research, Arlington, Virginia (contract no.: F49620-98-1-0139); Medical Free Electron Laser Program, Arlington, Virginia (contract nos.: F49620-01-1-0186, FWF P14218-PSY, FWF Y159-PAT, CRAF-1999-70549); Massachusetts Lions Eye Research Fund Inc., New Bedford, Massachusetts; Research to Prevent Blindness, New York, New York; and Carl Zeiss Meditec, Dublin, California.

    Drs Fujimoto and Schuman receive royalties from intellectual property licensed to Carl Zeiss Meditec.

    View full text